MetLife Investment Management’s RxSight RXST Stock Holding History

MetLife Investment Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$133K	Sell	21,555 -204	-0.9%	-$1.69K	﹤0.01%	2413
2025 Q4	$227K	Hold	21,759	–	–	﹤0.01%	2209
2025 Q3	$196K	Hold	21,759	–	–	﹤0.01%	2329
2025 Q2	$283K	Hold	21,759	–	–	﹤0.01%	1991
2025 Q1	$549K	Sell	21,759 -195	-0.9%	-$5.79K	﹤0.01%	1685
2024 Q4	$755K	Buy	21,954 +1,429	+7%	+$64.4K	﹤0.01%	1567
2024 Q3	$1.01M	Buy	20,525 +790	+4%	+$40.5K	0.01%	1380
2024 Q2	$1.19M	Buy	19,735 +5,217	+36%	+$298K	0.01%	1257
2024 Q1	$749K	Hold	14,518	–	–	0.01%	1457
2023 Q4	$585K	Hold	14,518	–	–	﹤0.01%	1596
2023 Q3	$405K	Hold	14,518	–	–	﹤0.01%	1765
2023 Q2	$418K	Buy	14,518 +2,408	+20%	+$53.6K	﹤0.01%	1816
2023 Q1	$202K	Hold	12,110	–	–	﹤0.01%	2217
2022 Q4	$153K	Hold	12,110	–	–	﹤0.01%	2405
2022 Q3	$145K	Hold	12,110	–	–	﹤0.01%	2478
2022 Q2	$171K	Buy	+12,110	New	+$160K	﹤0.01%	2427

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

MetLife Investment Management's RXST Position: Q1 2026 in Review

MetLife Investment Management reduced its RxSight (RXST) stake by 0.94% in Q1 2026, selling an estimated $1.69K and leaving 21,555 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

MetLife Investment Management first reported a position in RXST in Q2 2022 and has held it in 16 quarters since. The position peaked at $1.19M in Q2 2024. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

MetLife Investment Management held 21,555 shares of RxSight worth $133K as of Q1 2026.
MetLife Investment Management sold 204 RxSight shares in Q1 2026, an estimated $1.69K.
RxSight made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2413 holding.
MetLife Investment Management first reported a position in RxSight in Q2 2022 and has held it in 16 quarters since.
MetLife Investment Management's RxSight position peaked at $1.19M in Q2 2024.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.